Silvia de Sanjosé
Correspondence: Silvia de Sanjosé email@example.com
Infectious Agents and Cancer 2012, 7:37 doi:10.1186/1750-9378-7-37
(2013-02-04 14:41) Private Practice
As now better informed consumers who know the dire consequences of misinformation,
we feel compelled to comment on the Editorial entitled "HPV Prevention Series" authored
by Silvia de Sanjose . The author makes several statements which are at best, half-truths.
The statement that cervical cancer "remains to be the second leading cause of cancer
death in women in less developed regions of the world" is at best, a half-truth. It
fails to mention the women living in the developed countries where cervical cancer
death rates are very low. In the U.S.A., cervical cancer is 14th in frequency on the
list of causes of cancer death  and its death rate is 1.7 per 100,000 women; in
Australia and New Zealand its death rate is 1.4 and 1.6 per 100,000 respectively ,
and it is widely accepted that cervical cancer death only occurs in unscreened or
rarely screened women . Over-extrapolation of the clinical trial data and the benefits
obtained in a population with high cervical cancer rates compared to a population
living in the developed countries is inappropriate and misleading.
The statement "HPV is the necessary cause of cervical cancer"in the Editorial is also
a half-truth. The whole truth should be that HPV infection is not in itself a sufficient
cause of cervical cancer .
The author states that "major reduction of HPV related disease is feasible" through
such strategies as "routine HPV vaccination of pre-adolescent and young women." However
this statement is not supportable by scientific evidence as there is no pre or post
licensure research that HPV vaccines are more effective than Pap screening in reducing
incidences of cervical cancer or pre-cancerous lesions .
Furthermore, in developed countries, to achieve the claimed efficacy of 70% would
involve mass vaccination of every young girl between the ages of 9-12 to reduce one
death due to cervical cancer per every 100,000 girls vaccinated. The cost of vaccinating
100,000 young girls is $40,000,000-$100,000,000 in the U.S.A. at $400 to $1,000 per
vaccine regimen . It is not cost effective to invest so much money to prevent one
death caused by cervical cancer when the cancer occurs at an average age of 54 
and death only if it remains undiscovered and untreated. We have scientifically proven
safe and effective alternatives for preventing cervical cancer such as improved cervical
screening interventions which are far less harmful than the HPV vaccine. The serious
damage to the lives of some young vaccine recipients who experienced vaccine adverse
reactions and the monetary cost of the vaccine far outweigh the potential benefit
of the HPV vaccines.
We agree with the Editorial intent to invite articles "to widen our minds, to increase
our capacity for action and ultimately to increase the health of our population."
However those intentions cannot be achieved with half-truths and misinformation, or
by dismissing inconvenient truths as anti-vaccine activism or by ignoring science.
After undertaking our own research, we now realize that we were and continue to be
misinformed about the necessity, safety, efficacy and economic value of HPV vaccines.
It is the responsibility of scientific publications to ensure that the information
presented is accurate, balanced and unbiased. Toward that end and in the interest
of public health and safety, we submit our comments.
Emily Tarsell - Sparks, MD, USA firstname.lastname@example.org
Stephen Tunley - Sydney, Australia email@example.com
Identifications of 50 additional consumers who endorse these comments are available;
they also experienced dire consequences as a result of misinformation regarding hpv
 de Sanjose S: HPV Prevention Series. Editorial. Infect Agent and Canc 2012, 7:37.
 Janerich DT, Hadjimichael O, Schwartz PE, et al.: The screening histories of women
with invasive cervical cancer, Connecticut. Am J Public Health 1995, 85:
 Tomljenovic L, Shaw C: Too fast or not too fast; the FDA's approval of Merck's
vaccine Gardasil. J Law Med Ethics 2012 Fall, 40: 673-81.
 Lee NC: Testimony before the House Committee on Commerce, Subcommittee on Health
and Environment, March 16, 1999. http://www.hhs.gov/asl/testify/t990316b.html
Consumers who were misinformed about the necessity, safety and efficacy of HPV vaccines.
BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.